This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kontaridis, M. I. Articles by Bennett, A. M. Search for Related Content PubMed PubMed Citation Articles by Kontaridis, M. I. Articles by Bennett, A. M.

Role of SHP-2 in Fibroblast Growth Factor Receptor-Mediated Suppression of Myogenesis in C2C12 Myoblasts

Maria I. Kontaridis, Xiangdong Liu,^, Lei Zhang, and Anton M. Bennett^*

Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066

Received 24 August 2001/ Returned for modification 22 October 2001/ Accepted 27 February 2002

Ligand activation of the fibroblast growth factor receptor (FGFR) represses myogenesis and promotes activation of extracellular signal-regulated kinases 1 and 2 (Erks). The precise mechanism through which the FGFR transmits both of these signals in myoblasts remains unclear. The SH2 domain-containing protein tyrosine phosphatase, SHP-2, has been shown to participate in the regulation of FGFR signaling. However, no role for SHP-2 in FGFR myogenic signaling is known. In this study, we show that stimulation of C2C12 myoblasts with FGF-2 induces SHP-2 complex formation with tyrosyl-phosphorylated FGFR substrate 2 (FRS-2). Both the catalytic activity and, to a much lesser extent, the Grb2 binding-tyrosyl phosphorylation sites of SHP-2 are required for maximal FGF-2-induced Erk activity and Elk-1 transactivation. When overexpressed in C2C12 myoblasts, wild-type SHP-2, but not a catalytically inactive SHP-2 mutant, potentiates the suppressive effects of FGF-2 on muscle-specific gene expression. In addition, expression of a constitutively active mutant of SHP-2 is sufficient to prevent myogenesis. The constitutively active mutant of SHP-2 induces hyper-tyrosyl phosphorylation of FRS-2 but fails to stimulate or potentiate either FGF-2-induced Erk activation or Elk-1 transactivation. These data suggest that in myoblasts, SHP-2 represses myogenesis via a pathway that is independent of the Erks. We propose that SHP-2 plays a pivotal role in FGFR signaling in myoblasts via both Erk-dependent and Erk-independent pathways.

Present address: Curagen Corporation, Branford, CT 06405.

This article has been cited by other articles:

• Eminaga, S., Bennett, A. M. (2008). Noonan Syndrome-associated SHP-2/Ptpn11 Mutants Enhance SIRP{alpha} and PZR Tyrosyl Phosphorylation and Promote Adhesion-mediated ERK Activation. J. Biol. Chem. 283: 15328-15338 [Abstract] [Full Text]  
• Ha, C. H., Bennett, A. M., Jin, Z.-G. (2008). A Novel Role of Vascular Endothelial Cadherin in Modulating c-Src Activation and Downstream Signaling of Vascular Endothelial Growth Factor. J. Biol. Chem. 283: 7261-7270 [Abstract] [Full Text]  
• Odemis, V., Boosmann, K., Dieterlen, M. T., Engele, J. (2007). The chemokine SDF1 controls multiple steps of myogenesis through atypical PKC{zeta}. J. Cell Sci. 120: 4050-4059 [Abstract] [Full Text]  
• Zito, C. I., Qin, H., Blenis, J., Bennett, A. M. (2007). SHP-2 Regulates Cell Growth by Controlling the mTOR/S6 Kinase 1 Pathway. J. Biol. Chem. 282: 6946-6953 [Abstract] [Full Text]  
• Fornaro, M., Burch, P. M., Yang, W., Zhang, L., Hamilton, C. E., Kim, J. H., Neel, B. G., Bennett, A. M. (2006). SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth. J. Cell Biol. 175: 87-97 [Abstract] [Full Text]  
• Sasson, I. E., Stern, M. J. (2004). FGF and PI3 kinase signaling pathways antagonistically modulate sex muscle differentiation in C. elegans. Development 131: 5381-5392 [Abstract] [Full Text]  
• KUMAR, A., MURPHY, R., ROBINSON, P., WEI, L., BORIEK, A. M. (2004). Cyclic mechanical strain inhibits skeletal myogenesis through activation of focal adhesion kinase, Rac-1 GTPase, and NF-{kappa}B transcription factor. FASEB J. 18: 1524-1535 [Abstract] [Full Text]  
• Yu, S. J., Zheng, L., Ladanyi, M., Asa, S. L., Ezzat, S. (2004). Sp1-Mediated Transcriptional Control of Fibroblast Growth Factor Receptor 4 in Sarcomas of Skeletal Muscle Lineage. Clin. Cancer Res. 10: 6750-6758 [Abstract] [Full Text]  
• Kolli, S., Zito, C. I., Mossink, M. H., Wiemer, E. A. C., Bennett, A. M. (2004). The Major Vault Protein Is a Novel Substrate for the Tyrosine Phosphatase SHP-2 and Scaffold Protein in Epidermal Growth Factor Signaling. J. Biol. Chem. 279: 29374-29385 [Abstract] [Full Text]  
• Kontaridis, M. I., Eminaga, S., Fornaro, M., Zito, C. I., Sordella, R., Settleman, J., Bennett, A. M. (2004). SHP-2 Positively Regulates Myogenesis by Coupling to the Rho GTPase Signaling Pathway. Mol. Cell. Biol. 24: 5340-5352 [Abstract] [Full Text]  
• Sorci, G., Riuzzi, F., Arcuri, C., Giambanco, I., Donato, R. (2004). Amphoterin Stimulates Myogenesis and Counteracts the Antimyogenic Factors Basic Fibroblast Growth Factor and S100B via RAGE Binding. Mol. Cell. Biol. 24: 4880-4894 [Abstract] [Full Text]